These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 16949679

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH.
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J.
    Immunol Lett; 2006 Feb 15; 102(2):191-201. PubMed ID: 16242781
    [Abstract] [Full Text] [Related]

  • 7. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM.
    J Immunol; 1995 Jun 01; 154(11):5934-43. PubMed ID: 7538538
    [Abstract] [Full Text] [Related]

  • 8. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
    Yan Q, Cheung YK, Cheng SC, Wang XH, Shi M, Hu MH, Yong X.
    Gynecol Oncol; 2007 Jan 01; 104(1):199-206. PubMed ID: 17049969
    [Abstract] [Full Text] [Related]

  • 9. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.
    Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellström I, Hellström KE.
    J Immunol; 1992 Apr 15; 148(8):2617-21. PubMed ID: 1313847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.
    Steinberg T, Ohlschläger P, Sehr P, Osen W, Gissmann L.
    Vaccine; 2005 Jan 19; 23(9):1149-57. PubMed ID: 15629358
    [Abstract] [Full Text] [Related]

  • 12. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
    Dell K, Klein C, Gissmann L.
    Antivir Ther; 2008 Jan 19; 13(4):495-509. PubMed ID: 18672528
    [Abstract] [Full Text] [Related]

  • 13. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM.
    Vaccine; 2006 Jun 12; 24(24):5235-44. PubMed ID: 16675074
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response.
    Tan J, Yang NS, Turner JG, Niu GL, Maassab HF, Sun J, Herlocher ML, Chang AE, Yu H.
    Cancer Gene Ther; 1999 Jun 12; 6(4):331-9. PubMed ID: 10419051
    [Abstract] [Full Text] [Related]

  • 16. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T.
    Gene Ther; 2005 Sep 12; 12(18):1410-4. PubMed ID: 15843807
    [Abstract] [Full Text] [Related]

  • 17. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
    Lipford GB, Bauer S, Wagner H, Heeg K.
    Immunology; 1995 Feb 12; 84(2):298-303. PubMed ID: 7751006
    [Abstract] [Full Text] [Related]

  • 18. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 19. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM.
    Vaccine; 2006 Apr 05; 24(15):2880-93. PubMed ID: 16472545
    [Abstract] [Full Text] [Related]

  • 20. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X, Ladant D, Timmerman B, Leclerc C.
    Cancer Res; 2005 Jan 15; 65(2):641-9. PubMed ID: 15695409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.